Macular Pigment Optical Density in Primary Angle-closure Disease

Study on the Relationship Between Macular Pigment Optical Density and Primary Angle-closure Disease

Glaucoma is the leading cause of irreversible blindness in the world, and primary angle-closure glaucoma (PACG) is the most important type of glaucoma in Asia. Primary angle closure disease (PACD) is a group of diseases related to PACG, and the pathogenesis is still unclear. Macular pigment has the functions of filtering short-wavelength waves and anti-oxidation, which are related to visual function. Previous studies have found that the macular pigment density (MPOD) is significantly reduced in primary open-angle glaucoma. This project uses the single-wavelength reflection method to measure MPOD, observes the characteristics of PACD and the normal control group's changes in retinal MPOD, and explains the relationship between PACD's MPOD changes and angle-closure glaucoma optic nerve damage

Study Overview

Detailed Description

Observation index: Visual acuity,Intraocular pressure,Ophthalmoscope,MPOD,Visual field and OCT.

Inspection parameters of OCT:

  1. Retinal nerve fiber layer thickness
  2. Ganglion cell complex thickness
  3. Mean thickness of the central retina
  4. Mean defect

Study Type

Observational

Enrollment (Anticipated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Zhihong Huang, M.D
  • Phone Number: 02066615461 +8602066615461
  • Email: 575772588@qq.com

Study Contact Backup

  • Name: Chengguo Zuo, M.D,Ph.D
  • Phone Number: 02066615461 +8602066615461
  • Email: chengguozuo@163.com

Study Locations

    • Guangdong
      • Guangzhou, Guangdong, China, 510060
        • Recruiting
        • Zhognshan Ophthalmic Center, Sun Yat-sen University
        • Contact:
          • Zhihong O Huang
          • Phone Number: 02066615461 +8602066615461
          • Email: 575772588@qq.com
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 90 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Outpatients >=40 years old PACD

Description

Inclusion Criteria:

  • Experimental group:
  • (1) According to the diagnostic criteria of PACD
  • (2)History of peripheral iridectomy or trabeculectomy
  • (3)Over 40
  • (4)Phakic eyes
  • (5)Intraocular pressure is less than 21mmhg, more than one week
  • (6)Eyes with clear optical media.
  • Control group:
  • (1)No history of glaucoma and other eye diseases
  • (2)Phakic eyes
  • (3)Over 40
  • (4)Intraocular pressure10~21mmHg

Exclusion Criteria:

  • (1)History of corneal diseases
  • (2)History of eye tumor or other ophthalmic surgery
  • (3)Cataract
  • (4)Taking supplements containing lutein within 6 months
  • (5)Snellen's visual acuity was less than 6 / 20,the diopter is beyond ± 6 degrees

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Primary Angle Clousure Diseases Eyes
Over 40 years old, regardless of gender. Patients diagnosed with PACD (PACG or PAC or PACS) with phakic eyes. Peripheral iridectomy or trabeculectomy, more than 3 months after operation.
All participants underwent a detailed examination, including visual acuity, slit lamp biomicroscopy, direct ophthalmoscopy, optometry noncontact tonometry,MPOD measurement and optical coherence tomography (OCT) measurement
Matched Eyes
Healthy population matched by sex and age.
All participants underwent a detailed examination, including visual acuity, slit lamp biomicroscopy, direct ophthalmoscopy, optometry noncontact tonometry,MPOD measurement and optical coherence tomography (OCT) measurement

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Macular Pigment Optical Density(MPOD)Measurement
Time Frame: 3 months after surgery
A one-wavelength fundus reflectance method (Visucam 200; Carl Zeiss Meditec) was used for the detection of MPOD as previously described. The right or left eye was randomly selected for measurement. The parameters and profiles of MPOD in a 7-degree eccentricity that corresponded to a 4 mm diameter were evaluated and output. Parameters included max and mean optical density (OD), volume, and area. MaxOD and MeanOD with units "d.u." (initial of density units) were used for the analyses.
3 months after surgery
Retinal nerve fiber layer thickness
Time Frame: 3 months after surgery
Detection by optical coherence tomography (OCT). Circumpapillary RNFL scans were obtained using the standard 3.4 mm 12-degree circumpapillary nerve fiber layer scan protocol.We recorded superior, inferior, nasal, temporal, and total RNFL thickness.
3 months after surgery
Ganglion cell complex (GCC)thickness
Time Frame: 3 months after surgery
Detection by optical coherence tomography (OCT). The distance from the internal limiting membrane and outer edge of the outer plexiform layer was defined as GCC thickness.
3 months after surgery
Mean central retina thickness
Time Frame: 3 months after surgery
Detection by optical coherence tomography (OCT). CRT thickness was defined as distance between the internal limiting membrane and the inner edge of the retinal pigment epithelium.
3 months after surgery
Mean outer retinal thickness
Time Frame: 3 months after surgery
Outer retinal (OR) thickness was calculated by subtracting GCC thickness from CRT.
3 months after surgery
Visual Field Test
Time Frame: 3 months after surgery
The visual field test uses the 30-2 Threshold Test on the Humphrey Visual Field Analyzer.According to the mean deviation (MD) values generated by the software, three groups of disease severity were classified: the mild group with MD > -6 dB, the moderate group with MD between -6 and -12 dB, and the severe group with MD < -12 dB
3 months after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Visual acuity
Time Frame: 3 months after surgery
Use Snellen visual acuity chart to measure naked eye vision and best corrected vision
3 months after surgery
Intraocular pressure
Time Frame: 3 months after surgery
Using non-contact tonometer (NCT) measuring intraocular pressure
3 months after surgery
Cup/ Disk ( C/ D)
Time Frame: 3 months after surgery
determine the cup to disc ratio by ophthalmoscope
3 months after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Chengguo Zuo, Zhognshan Ophthalmic Center, Sun Yat-sen University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

November 11, 2021

Primary Completion (ANTICIPATED)

March 30, 2024

Study Completion (ANTICIPATED)

December 30, 2024

Study Registration Dates

First Submitted

February 11, 2022

First Submitted That Met QC Criteria

February 11, 2022

First Posted (ACTUAL)

February 23, 2022

Study Record Updates

Last Update Posted (ACTUAL)

February 13, 2023

Last Update Submitted That Met QC Criteria

February 9, 2023

Last Verified

February 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) needed to be keep security.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glaucoma

Clinical Trials on Ocular examination

3
Subscribe